My Companies
Notification
Account
Log Out
Login
Cipla received USFDA approval for generic Advair Diskus (fluticasone/salmeterol) in all strengths. US market size ~$908M; first DPI approval from its US network. Launch expected Q2 FY27, a key catalyst for US respiratory growth.